Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

NCT02494024 is registered in ClinicalTrials.gov with C2N Diagnostics as lead sponsor.

NCT NCT02494024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02494024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Lead sponsor
C2N Diagnostics
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2015
Completion date
August 31, 2016
Enrollment
32 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy